2018 American Transplant Congress

June 2-6, 2018 in Seattle, WA

View by Title View Sessions

View by Date

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z

B Cell Immune Repertoire Sequencing Identifies Pre-Transplant Rejection Risk

S. Pineda,^1,2 T. Sigdel,¹ J. Liberto,¹ K. Roskin,³ S. Robin,³ M. Sirota,² M. Sarwal.¹
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression

Q. Gao,¹ A. Mehta,² A. Guasch,² A. Ghali,² A. Kirk,¹ H. Xu.¹
B-Cell Depletion with Rituximab Exacerbates Anti-Donor CD4⁺ T-Cell Responses in Patients with Donor-Specific Anti-Human Leukocyte Antigen Antibodies

A. Tanaka, K. Ide, Y. Tanaka, M. Ohira, H. Tahara, S. Shimizu, H. Ohdan.
Bacterial Complications in Liver Transplant Recipients Undergoing Biliary Tract Manipulation: Effect of an Antibiotic Prophylaxis Protocol

C. Clifford, N. Theodoropoulos, J. Daly, L. Gibson, S. Mehta, H. Malik, A. Bozorgzadeh.
Balloon-Occluded Retrograde Transvenous Obliteration (BRTO) for the Treatment of Medically Refractory Hepatic Encephalopathy (HE) in Patients with ESLD and Significant Portal-Venous Shunting

N. Presser, J. DiNorcia, V. Agopian, H. Yersiz, D. Farmer, R. Busuttil, F. Kaldas.
Bariatric Surgery before and after Kidney Transplantation: Long-Term Weight-Loss and Allograft Outcomes

J. Cohen, M. Lim, C. Tewksbury, S. Torres Landa, J. Trofe-Clark, P. Abt, N. Williams, K. Dumon, S. Goral.
Barriers and Disparities in Listing for Pediatric Solid Organ Transplant

E. A. Steinberg,¹ C. Buchanan,¹ M. Wachs,¹ S. Schmiege.²
Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort

J. Schulte,¹ C. Richardson,¹ V. Stosor,² K. Cunningham,¹ C. D'Agostino,¹ C. Kane.¹
Basiliximab Induction in Simultaneous Liver-Kidney Transplant

C. Song, X. Luo, L. Pote, S. Strout, D. Segev, N. Desai, A. Gurakar, F. Navqi, J. Garonzik Wang.
Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation

A. Dao, S. Tremblay, A. Shields, A. Loethen, B. Abu Jawdeh, T. Diwan, A. Govil, E. Woodle, R. Alloway.
Belatacept in Kidney Transplant Recipients with Preformed Donor Specific Anti-HLA Antibodies: Results of the BELACOR Trial

C. Leibler,¹ F. Canoui,² M. Matignon,¹ E. Rondeau,³ A. Zarour,² A. Durrbach,⁴ S. Malard,⁵ P. Grimbert.¹
Belatacept Maintenance Immunosuppression Use and Outcomes in the Real-World Clinical Setting Using OPTN/UNOS Kidney Transplant Registry

S. Sanoff,¹ K. Ravindra,¹ W. Irish.^1,2
Belatacept-Refractory CD8⁺CD28^–CD38^hi Effector/Memory T Cells Are Targeted by mTOR Inhibition Leading to a Preferential Loss of CD40L

C. Castro Rojas,¹ A. Godarova,¹ A. Rike Shields,² R. Alloway,² M. Jordan,³ E. Woodle,² D. Hildeman.¹
Benefit of Anti-Hepatitis B Immunoglobulin(HBIG) Monotherapy Compared to HBIG Combined with Entecavir in Long Term Renal Function

J. Lee,¹ D. Kim,¹ J. Lee,² S. Kim,³ H. Lee,⁴ S. Song,⁵ J. Lee,¹ M. Ju,¹ G. Choi,¹ D. Joo,¹ J. Choi,¹ S. Kim,¹ Y. Jung.¹
Benefit of Patient Portal Usage in Non-High Risk Kidney Transplant Recipients

A. Osband, J. Machan, P. Morrissey.
BETA-2 Score is an Excellent Tool for Monitoring of Islet Allograft Function and Early Detection of Transplant Dysfunction

P. Bachul,¹ J. Gołębiewska,² L. Basto,¹ M. Kijek,¹ N. Fillman,¹ K. Cieply,¹ K. Golab,¹ L-.J. Wang,¹ M. Tibudan,¹ C. Thomas,¹ A. Dębska-Ślizień,² J. Fung,¹ P. Witkowski.¹
Biliary pH, Bicarbonate and Glucose Are Suitable Biomarkers of Bile Duct Viability during Normothermic Machine Perfusion of Human Donor Livers

A. Matton,^1,2 Y. de Vries,^1,2 L. Burlage,^1,2 R. van Rijn,^1,2 A. Gouw,³ V. de Meijer,¹ T. Lisman,² R. Porte.¹
Biochemistry Profiles Following Pig-to-Nonhuman Primate Liver Xenotransplantation

N. Louras, M. Patel, J. Shah, D. Sachs, P. Vagefi.
Bioinformatics Approach to the Development of a Novel Molecular Biomarker for Sub-Clinical Acute Rejection (subAR) in the Peripheral Blood Following Kidney Transplant (KT)

T. Whisenant,¹ S. Kurian,¹ M. Kandpal,² L. Zhao,² D. Ikle,³ B. Armstrong,³ J. Friedewald,² R. Heilman,⁴ E. Poggio,⁵ C. Marsh,¹ P. Baliga,⁶ N. Bridges,⁷ J. Odim,⁷ M. Brown,⁷ J. Charette,² S. Brietigam,² N. Sustento-Reodica,² D. Salomon,¹ M. Abecassis.²
Biomaterial-Based Localized and Controlled Delivery of Tofacitinib to Actuate Enhanced Costimulation Blockade and Promote Long-Term Transplant Survival

G. Raimondi,¹ P. Majumder,² V. Ivanova,¹ X. Calderon-Colon,³ A. Mirdad,¹ M. Iglesias Lozano,¹ W. Lee,¹ G. Brandacher,¹ J. Schneider,² J. Patrone.³
Biopsy Correlates of DSA in Antibody-Mediated Rejection: C4d vs Microvascular Inflammation Scores

C. Harris, L. Anderson, R. Khaim, J. Choudhuri, R. Shapiro, S. Florman, F. Salem, M. Menon.
BK Nephropathy in Non-Kidney Transplant Patients, a Case Series and Systematic Review of the Literature

A. Shah,¹ V. Kumar,² B. Laskin,^2,3 D. Sawinski,^1,2 J. Hogan.^1,2
BK Polyomavirus (BKPyV)-Specific T Cells as a Diagnostic and Prognostic Marker for BKPyV-Infections after Pediatric Kidney Transplantation

T. Ahlenstiel-Grunow,¹ M. Sester,² U. Sester,³ L. Pape.¹
BK Viremia in Simultaneous Kidney Pancreas Recipients: Single Center Experience

M. Alebrahim,¹ R. Pelletier,¹ A. Rajab,¹ G. Bumgardner,¹ R. Daloul,² C. Akateh,³ K. Washburn,¹ A. El-Hinnawi.¹
Blood Transfusion is a Critical Determinant of Resource Utilization and Total Hospital Cost in Liver Transplantation

C. Garcia, A. Dugan, D. Davenport, R. Gedaly.
Bloodstream Infection Caused by Enteric Organisms during the First 6 Months after Intestinal Transplant

J. Simkins,¹ J. Morillas-Rodriguez,¹ M. Morris,¹ L. Abbo,¹ J. Camargo,¹ R. Vianna.²
BLyS^-/- Rats to Prevent Alloantibody Production

N. Bath,¹ B. Verhoven,¹ N. Wilson,¹ S. Reese,² L. Coons,¹ S. Panzer,² A. Djamali,² R. Redfield.¹
Bone Marrow Derived Myeloid Suppressor Cell (BM-MDSCs) Prolongs the Graft Survival in Murine Heart Transplantation

K. Uchida, K. Fujimoto, K. Takeda, H. Bashuda, E. Yin, K. Okumura.
Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)

F. Eskandary,¹ H. Regele,² G. Bond,¹ N. Kozakowski,² M. Wahrmann,¹ L. Hidalgo,³ H. Haslacher,⁴ C. Kaltenecker,¹ M-.B. Aretin,⁵ R. Oberbauer,¹ J. Reeve,⁶ P. Halloran,⁶ G. Böhmig.¹
Brain Death Conditions Intensify Inflammation and Impair Metabolic Gene Expression

L. Zitur, P. Chlebeck, S. Odorico, T. Zens, J. Danobeitia, M. Eerhart, J. Reyes, A. D'Alessandro, K. Brunner, S. Capuano, L. Fernandez.
Brincidofovir for Disseminated Adenovirus in Kidney and Kidney-Pancreas Transplant Recipients: Report of a Case Series

L. Bowman, R. Baliga, C. Mayer.
Brincidofovir Was Used to Successfully Treat Adenovirus Infections in Solid Organ Transplant Recipients and Other Immunocompromised Patients

D. Florescu,¹ M. Grimley,² G. Papanicolaou,³ V. Prasad,⁴ E. Vainorius,⁵ G. Chittick,⁵ T. Brundage,⁵ G. Nichols.⁵
Broader Geographic Sharing and Impact on Lung Transplant Waitlist Time and Lung Allocation Score

W. Tsuang, M. Budev.
Building a Third-Party VST Bank from Scratch- The Cincinnati Experience

A. S. Nelson,¹ D. Heyenbruch,² X. Zhu,³ S. M. Davies,¹ C. Lutzko,³ C. Bollard,⁴ P. Hanley,⁴ T. Leemhuis,² L. Danziger-Isakov,⁵ M. S. Grimley.¹
Burden of Infectious Complications after Upper Extremity Allotransplantation: A Matched Cohort Study

A. Conrad,^1,2,3 P. Petruzzo,^4,5 J. Kanitakis,⁶ A. Gazarian,⁷ L. Badet,^3,8 P. Vanhems,^3,9 O. Thaunat,^1,3,10 E. Morelon,^1,3,10 A. Sicard.^1,3
Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients

I. Helanterä,¹ F. Ortiz,² R. Loginov,³ L. Mannonen,³ M. Lempinen,¹ I. Lautenschlager.³

Jump to: View All • a [b] c d e f g h i j k l m n o p q r s t u v w x y z